CY1108645T1 - Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη - Google Patents

Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη

Info

Publication number
CY1108645T1
CY1108645T1 CY20081101420T CY081101420T CY1108645T1 CY 1108645 T1 CY1108645 T1 CY 1108645T1 CY 20081101420 T CY20081101420 T CY 20081101420T CY 081101420 T CY081101420 T CY 081101420T CY 1108645 T1 CY1108645 T1 CY 1108645T1
Authority
CY
Cyprus
Prior art keywords
treatment
lymphopoietin
diagnosis
temperatures
temporary structural
Prior art date
Application number
CY20081101420T
Other languages
English (en)
Inventor
Martin Oft
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1108645T1 publication Critical patent/CY1108645T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Abstract

Θεραπεία για όγκους με χορηγώντας θυμική στρωματική λεμφοποιητίνη (TSLP). Διάγνωση νεοπλασμάτων τοποθετώντας σε επαφή ένα δείγμα με μια αντί-TSLP ή ένα υποδοχέα αντί-TSLP και ανίχνευση σχηματισμού ενός σύμπλοκου σντίσωμα:αντιγόνο.
CY20081101420T 2003-07-18 2008-12-09 Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη CY1108645T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48826303P 2003-07-18 2003-07-18
EP04778434A EP1651247B1 (en) 2003-07-18 2004-07-16 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin

Publications (1)

Publication Number Publication Date
CY1108645T1 true CY1108645T1 (el) 2014-04-09

Family

ID=34079411

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101420T CY1108645T1 (el) 2003-07-18 2008-12-09 Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη

Country Status (17)

Country Link
US (3) US20050048061A1 (el)
EP (1) EP1651247B1 (el)
JP (3) JP5436753B2 (el)
AT (1) ATE407691T1 (el)
AU (1) AU2004257781B2 (el)
CA (1) CA2532595A1 (el)
CY (1) CY1108645T1 (el)
DE (1) DE602004016522D1 (el)
DK (1) DK1651247T3 (el)
ES (1) ES2313076T3 (el)
HR (1) HRP20080617T3 (el)
MX (1) MXPA06000659A (el)
NZ (1) NZ544456A (el)
PL (1) PL1651247T3 (el)
PT (1) PT1651247E (el)
SI (1) SI1651247T1 (el)
WO (1) WO2005007186A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1129190E (pt) 1998-11-13 2007-08-08 Immunex Corp Adn e polipéptidos de tslp humanos.
PT1417231E (pt) 2001-07-23 2013-07-29 Immunex Corp Linfopoietina estromal tímica humana modificada
ATE407691T1 (de) * 2003-07-18 2008-09-15 Schering Corp Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
CA2671865C (en) * 2006-12-14 2017-01-10 Schering-Plough Ltd. Canine thymic stromal lymphopoietin protein and uses thereof
AR067045A1 (es) * 2007-06-20 2009-09-30 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
JPWO2012001889A1 (ja) * 2010-06-28 2013-08-22 国立大学法人東北大学 Ｔｓｌｐを恒常的に高発現する細胞、及び前記細胞を利用したｔｓｌｐ調節剤のスクリーニング方法
WO2012015696A1 (en) * 2010-07-26 2012-02-02 Baylor Research Institute Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
WO2014162007A2 (en) 2013-04-04 2014-10-09 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
US20210077581A1 (en) * 2017-04-04 2021-03-18 Loma Linda University Biologic for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
EP1897949B1 (en) 1998-09-21 2014-11-12 Merck Sharp & Dohme Corp. Human interleukin-B50. Therapeutic uses
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
PT1129190E (pt) * 1998-11-13 2007-08-08 Immunex Corp Adn e polipéptidos de tslp humanos.
JP2004519205A (ja) * 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
AU2002246502A1 (en) * 2000-11-17 2002-08-06 Hyseq, Inc. Nucleic acids and polypeptides
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
PT1417231E (pt) * 2001-07-23 2013-07-29 Immunex Corp Linfopoietina estromal tímica humana modificada
AU2003208888B2 (en) 2002-02-01 2006-10-19 Merck Sharp & Dohme Llc Uses of mammalian cytokine; related reagents
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
ATE407691T1 (de) * 2003-07-18 2008-09-15 Schering Corp Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)

Also Published As

Publication number Publication date
DE602004016522D1 (de) 2008-10-23
ES2313076T3 (es) 2009-03-01
ATE407691T1 (de) 2008-09-15
US20050048061A1 (en) 2005-03-03
MXPA06000659A (es) 2006-03-30
US8822405B2 (en) 2014-09-02
CA2532595A1 (en) 2005-01-27
JP2007314547A (ja) 2007-12-06
AU2004257781B2 (en) 2009-07-16
AU2004257781A1 (en) 2005-01-27
SI1651247T1 (sl) 2009-02-28
PT1651247E (pt) 2008-12-15
WO2005007186A1 (en) 2005-01-27
EP1651247B1 (en) 2008-09-10
PL1651247T3 (pl) 2009-04-30
JP2011236252A (ja) 2011-11-24
NZ544456A (en) 2009-02-28
DK1651247T3 (da) 2009-01-12
US20100015132A1 (en) 2010-01-21
EP1651247A1 (en) 2006-05-03
US20140370025A1 (en) 2014-12-18
JP5436753B2 (ja) 2014-03-05
JP2007534623A (ja) 2007-11-29
HRP20080617T3 (en) 2009-01-31

Similar Documents

Publication Publication Date Title
CY1108645T1 (el) Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη
CY1109468T1 (el) Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
ATE429320T1 (de) Medizinische vorrichtung und herstellungsverfahren dafür
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
DK1708994T3 (da) Aryloxyalkylcarbamatderivater, fremstilling og anvendelse herfra inden for terapi
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
IS7960A (is) Samsetningar og aðferðir til þess að meðhöndla krabbamein með því að nota IGSF9 og LIV-1
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
ATE474462T1 (de) Zusammensetzungen, kits und verfahren, bei denen eine zugesetzte borquelle eingesetzt wird
ITRM20030283A1 (it) Mezzi terapeutici e diagnostici per i papillomi.
SE0202257D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XVII
SE0201956D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy VI
SE0300293D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XXV
SE0201867D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy I
SE0201955D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy V
SE0202260D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XX
SE0300294D0 (sv) Novel sequence information and methods for its use in diagnosis therapy XXVI
SE0202255D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XV
SE0202251D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XI